PF614 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Pain
Conditions
Acute Pain
Trial Timeline
Oct 5, 2023 → Nov 15, 2023
NCT ID
NCT06629402About PF614 + Placebo
PF614 + Placebo is a phase 2 stage product being developed by Ensysce Biosciences for Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT06629402. Target conditions include Acute Pain.
What happened to similar drugs?
20 of 20 similar drugs in Acute Pain were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06629402 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Pain